Abstract 103P
Background
For patients (pts) with advanced BTC with progression on gemcitabine plus cisplatin (GemCis), fluoropyrimidine-based chemotherapy, including liposomal irinotecan (nal-IRI) plus fluorouracil and leucovorin (5-FU/LV) and 5-FU/LV plus oxaliplatin (FOLFOX) showed clinical benefit in prior randomized trials (NIFTY and ABC-06). However, there is no trial for head-to-head comparison among these agents.
Methods
We performed IPD meta-analysis of two multicenter, randomized trials performed in South Korea, which compared efficacy of second-line chemotherapy for advanced BTC after progression on GemCis, including the phase 2b NIFTY trial (nal-IRI plus 5-FU/LV vs. 5-FU/LV, NCT03524508) and the phase 2 FIReFOX trial (modified FOLFOX [mFOLFOX] vs. modified 5-FU/LV plus irinotecan [mFOLFIRI], NCT03464968). ITT population of the two trials were included and survival outcomes were compared between the 4 treatment groups by pairwise log-rank test. Hazards ratio (HR) adjusted by potential prognostic variables was estimated by Cox proportional hazards modeling with shared frailty to account for the trials effect.
Results
A total of 278 pts were included in this analysis (178 pts from the NIFTY trial and 99 pts from the FIReFOX trial). The nal-IRI plus 5-FU/LV group (n=88) showed significantly better overall survival compared to the mFOLFOX group (n=49, p = 0.02), mFOLFIRI group (n=50, p = 0.03), and 5-FU/LV group (n=90, p = 0.008). Multivariable analysis showed consistent trends with adjusted HR of 1.44 (95% CI 0.93-2.07, p = 0.11), 1.36 (95% CI 0.92-2.03, p = 0.13), and 1.52 (95% CI 1.37-1.09-2.10, p = 0.01), respectively. Also, nal-IRI plus 5-FU/LV group showed trends toward better progression-free survival compared to the other 3 groups with adjusted HR of 1.44 (95% CI 0.98-2.11, p = 0.06), 1.29 (95% CI 0.87-1.89, p = 0.20), and 1.88 (1.38-2.55, p < 0.001), respectively.
Conclusions
Nal-IRI plus 5-FU/LV showed better survival outcomes when compared to mFOLFOX, mFOLFIRI, or 5-FU/LV alone. Nal-IRI plus 5-FU/LV may be a preferable second-line regimen for advanced BTC pts without targetable genetic alterations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Servier.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17